Pyxis Oncology CEO Dr. Lara Sullivan steps down; board member Tom Civik appointed interim CEO

Pyxis Oncology, Inc.

Effective February 2, 2026, Dr. Lara Sullivan stepped down as President, CEO, and CMO of Pyxis Oncology.
Board appointed Thomas Civik, a current director, as Interim CEO; base salary $710K, target bonus 60%.
Civik receives initial option grant (1.1% of shares) vesting monthly over 12 months, plus top-up (0.4%) upon successful transaction.
Board launched search for permanent CEO; Civik previously led Five Prime through its $1.9B acquisition by Amgen.
Lead program MICVO continues Phase 1/2 trials for head and neck squamous cell carcinoma; clinical operations unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.